http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2010154716-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-277 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4045 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-428 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate | 2009-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2010154716-A |
| titleOfInvention | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE |
| abstract | 1. A pharmaceutical composition for treating Parkinson’s disease, comprising a pharmaceutically acceptable carrier and a combination of fixed doses of two active agents selected from compounds having either a neuroprotective or symptomatic effect or both symptomatic and neuroprotective effects on patients suffering from Parkinson’s disease, wherein the molar ratio The two compounds range from 1: 1 to 1: 100. ! 2. The pharmaceutical composition according to claim 1, characterized in that said compounds having either a neuroprotective or symptomatic effect, or both symptomatic and neuroprotective effects, are selected from two different groups of the following agents:! (i) dopamine receptor agonists; ! (ii) monoamine oxidase (MAO) inhibitors; ! (iii) levodopa alone or in combination with a decarboxylase inhibitor and / or catechol-O-methyltransferase (COMT) inhibitor; ! (iv) glutamate receptor agonists or antagonists; ! (v) spin traps; ! (vi) antioxidants; or ! (vii) 'anti-inflammatory agents. ! 3. The pharmaceutical composition according to claim 2, characterized in that:! (i) said dopamine receptor agonist is pramipexole, ropinirole, pyribedil, lisuride, cabergoline, apomorphine, rotigotine, bromocriptine or pergolide; ! (ii) said MAO inhibitor is a type B MAO inhibitor of a propargylamine group such as rasagiline and selegiline; ! (iii) said decarboxylase inhibitor is carbidopa or benserazide, and said COMT inhibitor is tolcapone or entacapone; and! (iv) the indicated glutamate receptor agonist or antagonist is |
| priorityDate | 2008-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 142.